Evidence map›Paper›PMID 34097715›Full record

ArticlePloS one2021

Prevalence of Mycobacterium tuberculosis infection as measured by the QuantiFERON-TB Gold assay and ESAT-6 free IGRA among adolescents in Mwanza, Tanzania.

Kidola Jeremiah, Eric Lyimo, Christian Ritz, George PrayGod, Kathryn Tucker Rutkowski, Karen Smith Korsholm, Morten Ruhwald, Dereck Tait, Harleen M S Grewal, Daniel Faurholt-Jepsen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 6 countries.

Kidola JeremiahMwanza Research Centre, National Institute for Medical Research, Mwanza, Tanzania.ORCID 0000-0001-7900-9689
Eric LyimoMwanza Research Centre, National Institute for Medical Research, Mwanza, Tanzania.
Christian RitzDepartment of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-5095-0624
George PrayGodMwanza Research Centre, National Institute for Medical Research, Mwanza, Tanzania.
Kathryn Tucker RutkowskiInternational AIDS Vaccine Initiative (IAVI,), New York City, New York, United States of America.
Karen Smith KorsholmDepartment of Infectious Immunology, Centre for Vaccine Research, Statens Serum Institut (SSI), Copenhagen, Denmark.
Morten RuhwaldDepartment of Infectious Immunology, Centre for Vaccine Research, Statens Serum Institut (SSI), Copenhagen, Denmark.
Dereck TaitInternational AIDS Vaccine Initiative (IAVI) NPC, Cape Town, South Africa.
Harleen M S GrewalDepartment of Clinical Science, BIDS Group, Faculty of Medicine, University of Bergen, Bergen, Norway.
Daniel Faurholt-JepsenDepartment of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0001-8561-0155
National Institute for Medical Research · TZStatens Serum Institut · DKHaukeland University Hospital · NOInternational AIDS Vaccine Initiative · USRigshospitalet · DKSouth African Tuberculosis Vaccine Initiative · ZAUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prevalence of latent tuberculosis infection (LTBI) is vastly higher than that of tuberculosis (TB) disease and this enormous reservoir of individuals with LTBI impacts the global TB control strategy. Adolescents are at greatest risk of TB infection and are thus an ideal target population for a potential effective TB vaccine to be added to the current BCG programme as it could reduce the number of latent infections and consequently the number of adults with TB disease. However, LTBI rates are often unknown for this population. This study aims to estimate the magnitude of LTBI and to determine if Tanzanian adolescents would be a good population for a prevention of TB infection trial.

methodsThis was a descriptive cross-sectional study that recruited 193 adolescents aged 12 and 16 years from government schools and directly from the community in Mwanza Region, Tanzania. Socio-demographic characteristics were collected for all enrolled participants. Blood was drawn and tested using QuantiFERON-TB Gold In-Tube (QFT-GIT), and Early Secretory Antigenic Target-6-Free Interferon-gamma Release Assay (ESAT-6 free IGRA). Concordance between QFT-GIT and ESAT-6 free IGRA was evaluated using the McNemar's test.

resultsOverall estimates of LTBI prevalence were 19.2% [95%CI, 14.1; 25.2] and 18.6% [95%CI, 13.6; 24.6] as measured by QFT-GIT IGRA and ESAT-6 free IGRA, respectively. The 16-year-old cohort had a higher LTBI prevalence (23.7% [95%CI, 16.1; 32.9]) as compared to 12-year-old cohort (14.6% [95%CI, 8.6; 22.7]) as measured by QFT-GIT IGRA. When measured by ESAT-6 Free IGRA, LTBI prevalence was 24.7% (95%CI, 16.9; 34.0) for the 16-year-old cohort and 12.5% (95%CI, 7.0; 20.3) among the 12-year-old cohort. According to both tests the prevalence of TB infection and the corresponding annual risk of tuberculosis infection (ARTI) and force of infection were high and increased with age. Of all enrolled participants, 97.4% had concordant results for QFT-GIT IGRA and ESAT-6 free IGRA (p = 0.65).

conclusionsThe prevalence of LTBI and the associated ARTI and force of infection among adolescents is high and increases with age in Mwanza Region. There was a high concordance between the QFT-GIT and the novel ESAT-6 free IGRA assays. These findings suggest Mwanza is a promising area to conduct novel TB vaccine research prevention of infection (POI) studies targeting adolescents.

Indexed as

AdolescentChildCohort StudiesCross-Sectional StudiesFemaleHumansInterferon-gamma Release TestsLatent TuberculosisMaleMycobacterium tuberculosisPrevalenceRisk FactorsSensitivity and SpecificityTanzaniaTuberculin TestTuberculosis VaccinesTuberculosis Vaccines

Identifiers

PMID34097715
PMCPMC8183982
OpenAlexW3169859285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.